✦ LIBER ✦

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial

✍ Scribed by Socinski, M. A.; Bondarenko, I.; Karaseva, N. A.; Makhson, A. M.; Vynnychenko, I.; Okamoto, I.; Hon, J. K.; Hirsh, V.; Bhar, P.; Zhang, H.; Iglesias, J. L.; Renschler, M. F.

Book ID: 115472541
Publisher: American Society of Clinical Oncology
Year: 2012
Tongue: English
Weight: 207 KB
Volume: 30
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2011.39.5848

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O-217 A randomized phase III trial of ge

O-217 A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) Non-Small Cell Lung Cancer (NSCLC)

✍ Treat, Joe; Chandra, Belani P.; Edelman, Martin; Socinski, Mark; Gonin, R.; Ansa 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 170 KB

A Randomized Phase III Trial of Combined

A Randomized Phase III Trial of Combined Paclitaxel, Carboplatin, and Radiation Therapy Followed by Weekly Paclitaxel or Observation for Patients With Locally Advanced Inoperable Non–Small-Cell Lung Cancer

✍ Dennis L. Carter; David Garfield; James Hathorn; Richard Mundis; Kristi A. Boehm 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 375 KB

A retrospective analysis of outcomes acr

A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer

✍ Treat, Joseph; Edelman, Martin J.; Belani, Chandra P.; Socinski, Mark A.; Monber 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 382 KB

O-082 A randomized phase III trial compa

O-082 A randomized phase III trial comparing ionafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)

✍ Blumenschein, G.; Ludwig, C.; Thomas, G.; Tan, E.; Fanucchi, M.; Santoro, A.; Cr 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 130 KB

Second-line (SL) weekly paclitaxel (P) i

Second-line (SL) weekly paclitaxel (P) in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing first-line (FL) carboplatin/paclitaxel (C/P)

✍ Socinski, M.A; Kies, M; Unger, P; Peterman, A; Gillenwater, H.H; Schell, M; Bakr 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 231 KB

Paclitaxel Poliglumex/Carboplatin Is Sim

Paclitaxel Poliglumex/Carboplatin Is Similar to Paclitaxel/Carboplatin as First-Line Treatment in Elderly Patients with Advanced Non–Small-Cell Lung Cancer and a Poor Performance Status

✍ G. Kesava Reddy; Chandra P. Belani; Vinay K. Jain 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 459 KB